Page last updated: 2024-08-05 11:01:02
dicarboximide
An imide in which the two acyl substituents on nitrogen are carboacyl groups.
ChEBI ID: 35356
Members (31)
| Member | Definition | Role |
|---|---|---|
| 4-(5-amino-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazol-3-amine | 4-(5-amino-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazol-3-amine | |
| 4-[5-(4-methyl-1,2,5-oxadiazol-3-yl)-1H-1,2,4-triazol-3-yl]-1,2,5-oxadiazol-3-amine | 4-[5-(4-methyl-1,2,5-oxadiazol-3-yl)-1H-1,2,4-triazol-3-yl]-1,2,5-oxadiazol-3-amine | |
| 4-amino-1,8-naphthalimide | 4-amino-1,8-naphthalimide | |
| 4-maleimido-2,2,6,6-tetramethylpiperidinooxyl | A member of the class of piperidines that is TEMPO carrying a maleimido group at position 4. | 4-maleimido-TEMPO |
| aminoglutethimide | A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position. | aminoglutethimide |
| aspartimide | A pyrrolidinone that is succinimide substituted by an amino group at position 3. | 3-aminosuccinimide |
| asperparaline a | An alkaloid isolated from Aspergillus aculeatus. | asperparaline A |
| bromosuccinimide | A five-membered cyclic dicarboximide compound having a bromo substituent on the nitrogen atom. | N-bromosuccinimide |
| cycloheximide | A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus. | cycloheximide |
| dichlozolinate | The ethyl ester of 3-(3,5-dichlorophenyl)-5-methyl-2,4-dioxo-1,3-oxazolidine-5-carboxylic acid. | ethyl 3-(3,5-dichlorophenyl)-5-methyl-2,4-dioxo-1,3-oxazolidine-5-carboxylate |
| ethosuximide | A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures. | ethosuximide |
| formothion | Formothion | |
| glutarimide | A dicarboximide that is piperidine which is substituted by oxo groups at positions 2 and 6. | piperidine-2,6-dione |
| iwr-1 endo | A dicarboximide having an endo bridged phthalimide structure, substituted at nitrogen by a 4-(quinolin-8-ylcarbamoyl)benzoyl group. | IWR-1-endo |
| iwr-1 exo | A dicarboximide having an exo bridged phthalimide structure, substituted at nitrogen by a 4-(quinolin-8-ylcarbamoyl)benzoyl group. It is a weak axin stabilizer, an analogue of IWR-1-endo. | IWR-1-exo |
| lenalidomide | A dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. Inhibits the secretion of TNF-alpha. | lenalidomide |
| lurasidone | An N-arylpiperazine that is (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-(piperazin-1-ylmethyl)cyclohexyl]methyl}hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione in which position N4 of the piperazine ring is substituted by a 1,2-benzothiazol-3-yl group. Lurasidone is used (generally as the hydrochloride salt) as an atypical antipsychotic for the treatment of schizophrenia. | lurasidone |
| maleimide | A cyclic dicarboximide in which the two carboacyl groups on nitrogen together with the nitogen itself form a 1H-pyrrole-2,5-dione structure. | maleimide |
| malyngamide A | malyngamide A | |
| n-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide | 3-maleimido-PROXYL | |
| N-(3,4-dihydro-2H-pyrrol-5-yl)-5-(2-furanyl)-1,3,4-oxadiazol-2-amine | N-(3,4-dihydro-2H-pyrrol-5-yl)-5-(2-furanyl)-1,3,4-oxadiazol-2-amine | |
| n-chlorosuccinimide | A five-membered cyclic dicarboximide compound having a chloro substituent on the nitrogen atom. | N-chlorosuccinimide |
| n-iodosuccinimide | A five-membered cyclic dicarboximide compound having an iodo substituent on the nitrogen atom. | N-iodosuccinimide |
| perylenediimide | The 3,4,9,10-tetracarboxylic diimide derivative of perylene. | perylenediimide |
| piplartine | Piplartine | |
| pomalidomide | An aromatic amine that is thalidomide substituted at position 4 on the isoindole ring system by an amino group. Used for the treatment of multiple myeloma in patients who failed to respond to previous therapies. | pomalidomide |
| s 23121 | A dicarboximide that is 4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione in which the nitrogen has been substituted by a 5-(but-3-yn-2-yloxy)-4-chloro-2-fluorophenyl group. | 2-[5-(but-3-yn-2-yloxy)-4-chloro-2-fluorophenyl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione |
| s 53482 | A benzoxazine that is N-(prop-2-yn-1-yl)-2H-1,4-benzoxazin-3(4H)-one which is substituted at position 6 by a 1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl group and at position 7 by a fluorine. A protoporphyrinogen oxidase inhibitor, it is used for the control of weeds in soya, peanuts, and a variety of vegetable and fruit crops. | flumioxazin |
| succinimide | A dicarboximide that is pyrrolidine which is substituted by oxo groups at positions 2 and 5. | succinimide |
| tandospirone | A dicarboximide that is (3aR,4S,7R,7aS)-hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione which is substituted by a 4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl group at position 2. It is a potent and selective 5-HT1A receptor partial agonist (Ki = 27 nM). | tandospirone |
| vinclozolin | A member of the class of oxazolidinones that is 5-ethenyl-5-methyl-2,4-oxazolidinedione in which the imide hydrogen is replaced by a 3,5-dichlorophenyl group. | 3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-2,4-oxazolidinedione |
Research
Studies (27,573)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11,394 (41.32) | 18.7374 |
| 1990's | 5,989 (21.72) | 18.2507 |
| 2000's | 4,048 (14.68) | 29.6817 |
| 2010's | 4,636 (16.81) | 24.3611 |
| 2020's | 1,506 (5.46) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,064 (3.68%) | 5.53% |
| Reviews | 1,380 (4.78%) | 6.00% |
| Case Studies | 823 (2.85%) | 4.05% |
| Observational | 37 (0.13%) | 0.25% |
| Other | 25,587 (88.56%) | 84.16% |